Related Experiment Videos
[Cotrimoxazole induced dermatitis and curative treatment of AIDS pneumocystosis]
1Service des Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpètrière, Paris.
Abstract:
Adverse cutaneous reactions frequently occur during the treatment of AIDS associated pneumocystosis by trimethoprime-sulfamethoxazole. The most common form is a maculous rash. Treating throughout the duration of hypersensitivity may lead to potentially lethal Stevens-Johnson and Lyell syndromes. Slow acetylator phenotype, a glutathion deficiency and a history of adverse cutaneous reactions have been identified as risk factors of cutaneous reactions. An adjuvant corticosteroid therapy decreases the frequency of adverse cutaneous reactions during the treatment of hypoxaemic pneumocystosis by trimethoprim-sulfamethoxazole.
Insights
Adverse cutaneous reactions are common during trimethoprim-sulfamethoxazole treatment for pneumocystosis in AIDS patients. Adjuvant corticosteroid therapy can reduce the frequency of these reactions.
Area of Science:
- Pharmacology
- Dermatology
- Infectious Diseases
Context:
- Trimethoprim-sulfamethoxazole is a primary treatment for Pneumocystis pneumonia (PCP) in individuals with Acquired Immunodeficiency Syndrome (AIDS).
- Adverse cutaneous reactions, including maculous rash, are frequent during this treatment.
- Severe reactions like Stevens-Johnson syndrome and Lyell syndrome can be life-threatening.
Purpose:
- To identify risk factors for adverse cutaneous reactions during trimethoprim-sulfamethoxazole therapy for PCP in AIDS patients.
- To evaluate the efficacy of adjuvant corticosteroid therapy in mitigating these reactions.
Summary:
- Adverse cutaneous reactions are common in AIDS patients treated with trimethoprim-sulfamethoxazole for Pneumocystis pneumonia.
- Risk factors include slow acetylator phenotype, glutathione deficiency, and a prior history of cutaneous reactions.
- Adjuvant corticosteroid therapy was found to decrease the incidence of these adverse reactions.
Impact:
- This research highlights the need for vigilant monitoring of skin reactions during trimethoprim-sulfamethoxazole treatment for PCP in AIDS patients.
- Findings suggest that corticosteroid co-administration may be a valuable strategy to improve treatment tolerability and patient safety.
- Understanding risk factors can aid in personalized treatment approaches and prevention strategies for adverse drug reactions.